ArticleCureus2025
Comprehensive Bioinformatic Analysis of Epithelial-Mesenchymal Transition (EMT) Network-Related microRNAs As Candidate Signatures in Prostate Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is an adenocarcinoma that involves epithelial-mesenchymal transition (EMT) for metastasis. To uncover novel insights into the development of prostate tumors and to identify important genes and putative microRNAs (miRs) for patient care, this study performed an in-depth bioinformatics analysis using dbDEMC3.0 (Zhejiang University, Hangzhou, China), MIENTURNET (University of Rome Tor Vergata, Rome, Italy), and DIANA-miTED (University of Thessaly, Thessaly, Greece) to explore miRs regulating tumorigenesis, proliferation, and potential therapeutic targets. A total of 373 differently expressed miRs were examined in this study, of which 87 had significant upregulation and 85 had significant downregulation. Our results from the MIENTURNET software showed that miR-141-3p, miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-203a-3p, miR-429, miR-34a-5p, and miR-509-3-5p interact with the transcription factors CDH1, CDH2, SNAI1, ZEB1, and ZEB2, which play a significant role in the core EMT regulatory network. The Encyclopedia of RNA Interactomes (ENCORI) miR-target interaction co-expression analysis observed that miR-34a-5p had a strong interaction with CDH1 as compared to other genes. The results of DIANA-plasmiR analysis showed that miR-34a-5p is a useful prognostic and diagnostic biomarker. Our results suggest that this study advances our knowledge of the molecular mechanism underlying prostate adenocarcinoma and that the interaction between the EMT gene and differentially expressed miR (DEmiR) in prostate adenocarcinoma may represent a target for prostate cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.